Hypertriglyceridemia - Pipeline Insight, 2021
This report can be delivered to the clients within 3-4 Business Days
DelveInsight’s, “Hypertriglyceridemia - Pipeline Insight, 2021,” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Hypertriglyceridemia: Overview
Hypertriglyceridemia refers to an elevated level of triglycerides (a type of lipid) in the bloodstream, a condition that increases the risk of coronary artery disease. The triglycerides found in our bloodstream are a mixture of triglycerides that have been obtained from the diet and those produced in the body to provide an energy source. Hypertriglyceridemia is often caused or worsened by factors such as obesity, poorly controlled diabetes and a sedentary lifestyle. The most common reasons for hypertriglyceridemia developing are obesity, lack of physical activity, type 2 diabetes, metabolic syndrome and familial hyperlipidemia, a genetic condition that causes high triglycerides and low levels of the “good” cholesterol, HDL (high-density lipoprotein).
'Hypertriglyceridemia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hypertriglyceridemia pipeline landscape is provided which includes the disease overview and Hypertriglyceridemia treatment guidelines. The assessment part of the report embraces, in depth Hypertriglyceridemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypertriglyceridemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Hypertriglyceridemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hypertriglyceridemia Emerging Drugs
Further product details are provided in the report……..
Hypertriglyceridemia: Therapeutic Assessment
This segment of the report provides insights about the different Hypertriglyceridemia drugs segregated based on following parameters that define the scope of the report, such as:
Hypertriglyceridemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hypertriglyceridemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypertriglyceridemia drugs.
Hypertriglyceridemia Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Hypertriglyceridemia - Pipeline Insight, 2021,” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Hypertriglyceridemia: Overview
Hypertriglyceridemia refers to an elevated level of triglycerides (a type of lipid) in the bloodstream, a condition that increases the risk of coronary artery disease. The triglycerides found in our bloodstream are a mixture of triglycerides that have been obtained from the diet and those produced in the body to provide an energy source. Hypertriglyceridemia is often caused or worsened by factors such as obesity, poorly controlled diabetes and a sedentary lifestyle. The most common reasons for hypertriglyceridemia developing are obesity, lack of physical activity, type 2 diabetes, metabolic syndrome and familial hyperlipidemia, a genetic condition that causes high triglycerides and low levels of the “good” cholesterol, HDL (high-density lipoprotein).
'Hypertriglyceridemia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hypertriglyceridemia pipeline landscape is provided which includes the disease overview and Hypertriglyceridemia treatment guidelines. The assessment part of the report embraces, in depth Hypertriglyceridemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypertriglyceridemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Hypertriglyceridemia R&D. The therapies under development are focused on novel approaches to treat/improve Hypertriglyceridemia.
This segment of the Hypertriglyceridemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hypertriglyceridemia Emerging Drugs
- ARO-APOC3: Arrowhead Pharmaceuticals
- MND-21: Mochida Pharmaceutical
Further product details are provided in the report……..
Hypertriglyceridemia: Therapeutic Assessment
This segment of the report provides insights about the different Hypertriglyceridemia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Hypertriglyceridemia
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Hypertriglyceridemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hypertriglyceridemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypertriglyceridemia drugs.
Hypertriglyceridemia Report Insights
- Hypertriglyceridemia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Hypertriglyceridemia drugs?
- How many Hypertriglyceridemia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hypertriglyceridemia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hypertriglyceridemia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Hypertriglyceridemia and their status?
- What are the key designations that have been granted to the emerging drugs?
- Arrowhead Pharmaceuticals
- Mochida Pharmaceutical
- Ionis Pharmaceuticals
- 89bio
- Regeneron Pharmaceuticals
- Acasti Pharma Inc.
- Staten Biotechnology BV
- NorthSea Therapeutics B.V.
- Afimmune
- Rivus Pharmaceuticals
- Novo Nordisk
- Viking Therapeutics
- Liminal BioSciences
- Matinas BioPharma
- Arbutus Biopharma
- Better Therapeutics
- ARO-APOC3
- MND-21
- IONIS-APOCIII-LRx
- BIO89-100
- Evinacumab
- CaPre
- STT-5058
- NST-1024
- DS102
- AKCEA-APOCIII-LRx
- NST-4016
- BT-005
- HU 6
- TKM-HTG
- COR 003
- MAT-9001
- VK 1430
- PBI 4050
Introduction
Executive Summary
Hypertriglyceridemia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Hypertriglyceridemia – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
MND-21: Mochida Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
ARO-APOC3: Arrowhead Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
ARGX 116: argenx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
VK 1430: Viking Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Hypertriglyceridemia Key Companies
Hypertriglyceridemia Key Products
Hypertriglyceridemia- Unmet Needs
Hypertriglyceridemia- Market Drivers and Barriers
Hypertriglyceridemia- Future Perspectives and Conclusion
Hypertriglyceridemia Analyst Views
Hypertriglyceridemia Key Companies
Appendix
Executive Summary
Hypertriglyceridemia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Hypertriglyceridemia – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
MND-21: Mochida Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
ARO-APOC3: Arrowhead Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
ARGX 116: argenx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
VK 1430: Viking Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Hypertriglyceridemia Key Companies
Hypertriglyceridemia Key Products
Hypertriglyceridemia- Unmet Needs
Hypertriglyceridemia- Market Drivers and Barriers
Hypertriglyceridemia- Future Perspectives and Conclusion
Hypertriglyceridemia Analyst Views
Hypertriglyceridemia Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Hypertriglyceridemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Hypertriglyceridemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Hypertriglyceridemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Hypertriglyceridemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products